Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion. The German Institute for Quality and ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and ...

Faricimab increased treatment intervals and decreased CST in previously treated nAMD patients, but BCVA remained unchanged. The study included 88 eyes from 73 patients, with a mean follow-up of 30 ...

Roche said the TENAYA and LUCERNE studies achieved their goal, with faricimab producing comparable improvements in vision when dosed every 16 weeks, compared with Bayer/Regeneron’s Eylea ...

However, recent real-world data for faricimab has confirmed its efficacy and safety. “We’ll await longer-term data to look at really that annualized injection burden and long-term treatment ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined in an early benefit assessment whether faricimab offers patients benefits over ranibizumab or aflibercept.

Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody showed comparable results in diabetic macular oedema (DME) but with half the ...